About
UCB appears at No. 828 in the 2026 Global 2000, a multi-factor ranking based on sales, profits, assets and market value. The company is headquartered in Brussels, Belgium and operates primarily in drugs & biotechnology. Reported figures used for the ranking include $8.7B in sales, $1.8B in profit, $21.3B in assets and a market value of $52.5B.